Celcuity Inc. (CELC)
CELCDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How CELC's past catalysts played out
Gedatolisib
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Arm B: Ribociclib + Fulvestrant
Breast Cancer
Talazoparib
TNBC - Triple-Negative Breast Cancer
LY3023414
Endometrial Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Gedatolisib | Phase 3 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | - | - |
Arm B: Ribociclib + Fulvestrant | Phase 3 | Breast Cancer | - | - |
Talazoparib | Phase 2 | TNBC - Triple-Negative Breast Cancer | - | - |
LY3023414 | Phase 2 | Endometrial Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Celcuity Inc. (CELC)'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Celcuity Inc. (CELC)'s (CELC) pipeline across Phase 3, Phase 2. Its lead program is Gedatolisib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celcuity Inc. (CELC)'s next FDA catalyst?→
Celcuity Inc. (CELC)'s (CELC) next tracked catalyst is a Earnings expected November 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CELC biotech catalysts?→
Add CELC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celcuity Inc. (CELC)'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.